BPMC earnings call for the period ending December 31, 2019.
News & Analysis: Blueprint Medicines
Meet EQRx, a biotech startup founded by an industry legend who wants to develop new therapies sold at generic prices, undermining the drug industry's profits.
They have what deep-pocketed pharmaceutical giants want.
Here's why you might want to buy Amarin and Blueprint Medicines as soon as possible.
Two presentations at the World Conference on Lung Cancer will make a big difference for at least four different drugmakers.
Investors have run back to the stock after promising clinical results.
BPMC earnings call for the period ending June 30, 2019.
Despite already massive gains this year, shares of these drugmakers could keep on climbing.
It looks like this biotech has what big-pharma companies have been eager to acquire.
Here's why these very different drugmakers could both receive a big buyout offer before the end of 2019.